In the context of the COVID-19 epidemic showing signs of increasing again in some provinces and cities, the epidemic situation still has many complicated developments. To promptly respond and ensure the supply of drugs for disease prevention and control, the Department of Drug Administration (Ministry of Health) has issued specific instructions to drug production and trading units.
The Drug Administration of Vietnam requires units to increase the supply of drugs and pharmaceutical ingredients. Units need to proactively contact medical examination and treatment facilities to grasp the needs, thereby developing a drug production and trading plan. The goal is to ensure timely supply of COVID-19 drugs and essential drugs for COVID-19 patients, especially symptomatic drugs, respiratory support drugs and emergency resuscitation drugs. These drugs need to be provided continuously, not allowing local shortages or supply interruptions.
According to Decision No. 2671/QD-BYT dated June 26, 2023 of the Ministry of Health on Guidelines for diagnosis and treatment of COVID-19, pharmaceutical production and trading units need to pay special attention to ensuring adequate medicine to treat symptoms and support respiratory facilities, helping medical facilities effectively respond to the epidemic.
In addition, for drugs with scarce supply, the Drug Administration will prioritize the quick settlement of the issuance of circulation registration certificates and import licenses. This is to ensure adequate medicine for medical examination and treatment facilities when requested by relevant units.
With the above instructions, the Drug Administration hopes to meet the demand for COVID-19 treatment drugs during the peak period of the epidemic, contributing to protecting public health and maintaining effective epidemic prevention.
